ResMed Inc. ($RMD) Stock Forecast: Down 5.1% Today

What is ResMed Inc.?

ResMed (RMD) is a company in the sleep and respiratory care sector, recognized for its innovative healthcare solutions. There was a notable decline in the company's stock performance in the market.

Why is ResMed Inc. going down?

RMD stock is down 5.1% on Feb 12, 2026 19:12

• The stock's decline could be linked to CEO Michael Farrell selling a significant number of shares, leading to investor concerns regarding the company's future.
• The reduction in ResMed's stake by Baader Bank Aktiengesellschaft may have also fueled negative sentiment, despite the company surpassing quarterly expectations.
• Market reaction to the ongoing clinical trial of ResMed's new software tool for sleep apnea patients might be influencing investor decisions, awaiting substantial results.
• Insider selling, institutional adjustments, and trial progress are potential factors contributing to today's bearish movement in ResMed's stock.

RMD Price Chart

RMD Technical Analysis

RMD News

ResMed Tests Smart CPAP Pressure Tool in New Sleep Apnea Trial

ResMed (RMD) is conducting a new clinical trial to test a software tool, the APAP Pressure Match tool, designed to improve CPAP pressure settings for sleep apnea patients. This tool uses personalized data to fine-tune pressure ranges, aiming to be as effective as standard methods while simplifying treatment setup for clinicians. The trial, currently in the setup phase and not yet recruiting, signifies ResMed's focus on software-driven personalization in sleep and respiratory care, which could enhance adoption and pricing power if successful.

https://www.tipranks.com/news/company-announcements/resmed-tests-smart-cpap-pressure-tool-in-new-sleep-apnea-trial

Baader Bank Aktiengesellschaft Sells 8,794 Shares of ResMed Inc. $RMD

Baader Bank Aktiengesellschaft significantly reduced its stake in ResMed Inc. by selling 8,794 shares, lowering its holdings to 10,417 shares valued at $2.82 million. This comes as ResMed outperformed quarterly expectations with strong EPS and revenue growth, and analysts maintain a "Moderate Buy" rating with a consensus target price of $299.27. Despite institutional buying, company insiders have recently sold over $4.6 million in shares.

https://www.marketbeat.com/instant-alerts/filing-baader-bank-aktiengesellschaft-sells-8794-shares-of-resmed-inc-rmd-2026-02-11/

Michael Farrell Sells 4,991 Shares of ResMed (NYSE:RMD) Stock

Michael Farrell, CEO of ResMed (NYSE:RMD), sold 4,991 shares of the company's stock on February 9th, 2026, for a total value of $1,366,435.98 at an average price of $273.78 per share. Following this transaction, Farrell's direct ownership in the company decreased by 1.06%, now totaling 466,223 shares valued at over $127 million. The article also provides an overview of ResMed's financial performance, stock metrics, recent dividend announcement, institutional ownership changes, and analyst ratings.

https://www.marketbeat.com/instant-alerts/michael-farrell-sells-4991-shares-of-resmed-nysermd-stock-2026-02-10/

Zacks.com featured highlights include Amphenol, GE Aerospace, ResMed and Ameriprise Financial

This article highlights four Growth at a Reasonable Price (GARP) stocks: Amphenol, GE Aerospace, ResMed, and Ameriprise Financial, recommended by Zacks Investment Research for their potential to offer significant returns. The GARP strategy combines elements of value and growth investing, targeting undervalued stocks with strong prospects and stable growth rates. Each company's recent performance, strategic initiatives, and analyst outlook are discussed to demonstrate their alignment with GARP metrics.

https://www.theglobeandmail.com/investing/markets/stocks/AMP/pressreleases/124547/zackscom-featured-highlights-include-amphenol-ge-aerospace-resmed-and-ameriprise-financial/

The Truth About ResMed Inc (NYSE - replacing with ROST): Why Everyone Is Suddenly Watching This Stoc

This article discusses the recent market interest in ResMed Inc (RMD) and Ross Stores (ROST), analyzing whether they represent genuine investment opportunities or are simply passing hype. It compares the two companies' business models—ResMed in sleep and respiratory tech versus Ross Stores in off-price retail—and evaluates their stock performance, market perception, and suitability for different types of investors. The author emphasizes the importance of fundamental analysis over social media buzz for long-term investment decisions.

https://www.ad-hoc-news.de/news/ueberblick/the-truth-about-resmed-inc-nyse-replacing-with-rost-why-everyone-is/68569321

Trending Today

ResMed Inc. Price History

30.00.2026 - RMD Stock was down 0.8%

• The strong bearish movement in ResMed's stock today could be attributed to profit-taking by investors after a period of positive performance and price appreciation.
• Despite the impressive Q2 results and increased institutional interest in the company's stock, the notable insider selling by CEO Michael J. Farrell and others might have raised concerns among investors about the future outlook of the company.
• Additionally, the market may be reacting to the Hold rating reiterated by an independent analyst, indicating a more cautious stance on the stock despite the positive financial performance.
• Overall, the bearish movement could be a result of a combination of factors, including profit-taking, insider selling, and cautious analyst sentiment, leading to a temporary dip in the stock price.

13.00.2026 - RMD Stock was down 0.3%

• Bogart Wealth LLC notably increased its stake in ResMed Inc., while company insiders have been selling shares possibly suggesting differing views on the company's potential.
• ResMed's robust Q3 earnings report and revenue growth might have initially boosted investor confidence, but recent insider selling by the CEO and a director could have raised concerns.
• The sale of shares by ResMed director Peter C. Farrell under a pre-arranged trading plan, amid varied analyst ratings, could have intensified the negative sentiment surrounding the stock.
• Despite the positive earnings and institutional investments, the mixture of analyst ratings, insider selling, and market apprehensions about the company's future likely contributed to the bearish movement in ResMed's stock price today.

05.00.2026 - RMD Stock was up 1.3%

• The significant insider selling and institutional ownership of ResMed Inc. could have initially raised concerns among investors, but the company's ability to surpass EPS and revenue expectations likely reassured the market.
• ResMed's strategic shift towards a connected ecosystem for sleep and respiratory care may have sparked investor optimism about the company's long-term growth potential and competitive edge.
• The high institutional ownership, particularly with influential shareholders like The Vanguard Group, Inc., suggests a level of confidence in ResMed's future performance, potentially contributing to the bullish movement in the stock.
• Overall, the combination of positive financial results, strategic positioning in the market, and strong institutional support likely drove the bullish momentum in ResMed's stock today.

24.03.2025 - RMD Stock was up 5.1%

• ResMed reported stellar third-quarter fiscal 2025 results, surpassing earnings and revenue estimates, showcasing strong execution across all business areas.
• The appointment of Salli Schwartz as Chief Investor Relations Officer could have instilled confidence in investors, signaling a focus on transparent communication and investor relations.
• The positive market reaction indicates that investors are optimistic about ResMed's future prospects and growth trajectory, driven by robust financial performance and strategic leadership appointments.

31.09.2025 - RMD Stock was down 6.1%

• Despite ResMed (RMD) beating earnings and revenue estimates for Q1, the stock experienced a bearish movement.
• The options market activity suggests that there might be some uncertainty or negative sentiment surrounding the stock.
• Investors may be reacting to factors beyond the quarterly performance, such as future growth projections or market conditions.
• The bearish movement could also be influenced by profit-taking activities following a period of positive performance.

04.01.2026 - RMD Stock was up 2.6%

• Institutional investors acquiring significant stakes in ResMed Inc. indicate growing confidence in the company's future prospects, contributing to the bullish movement.
• Despite insider selling trends, the positive quarterly results and dividend announcement have likely boosted investor sentiment towards ResMed.
• Emphasizing ResMed as a stable long-term investment in the healthcare sector reinforces the positive market movement, attracting more investors to the stock.
• The overall bullish sentiment towards ResMed is further supported by the insider sell alert, which, despite the selling activity, did not deter investors, possibly due to the company's strong fundamentals and growth potential.

08.03.2025 - RMD Stock was down 5.1%

• ResMed recently introduced NightOwl, an FDA-approved home sleep apnea test in the US. Nevertheless, the stock faced a decline in the market.
• Speculation from sources suggests the stock may not see further growth despite positive earnings estimate revisions.
• Investor expectations for ResMed's performance could have driven a sell-off of the stock following news of the successful product launch.

04.07.2025 - RMD Stock was up 4.0%

• ResMed (RMD) exceeded expectations in Q2 earnings, outperforming projections for both earnings per share and sales.
• Analysts have raised their forecasts for the company following the strong earnings report, signaling confidence in its future performance.
• Surpassing estimates for Q4 earnings and revenue reinforces ResMed's market position and indicates potential for further growth.
• The uptick in ResMed's stock price reflects its robust financial results and positive outlook for the future.

10.02.2025 - RMD Stock was up 5.2%

• The bullish movement in RMD can be attributed to the strong sales performance of its mask and device products, showcasing the company's ability to meet market demand effectively.
• The success of ResMed's cloud-connected AirSense platform has also played a significant role in driving investor confidence and contributing to the stock's impressive rally.
• Despite concerns about increasing debt levels, the market seems to be focusing more on the company's product innovation and industry outperformance, leading to the bullish movement in the stock.

11.01.2026 - RMD Stock was down 6.1%

• Significant selling activity by Baader Bank Aktiengesellschaft and CEO Michael Farrell, reducing their stakes in ResMed, might have signaled a lack of confidence in the company's future performance, contributing to the bearish trend.
• Despite ResMed's strong quarterly results and analyst recommendations, insider selling totaling over $4.6 million could have raised concerns among investors about the company's growth potential.
• The high institutional ownership of 73% in ResMed indicates that any changes in their positions could heavily influence the stock price, potentially leading to a bearish sentiment as seen today.
• A comparison with Ross Stores in discussions about market interest highlights the contrasting performance and market perception between the two companies, potentially leading investors to shift their focus away from ResMed, contributing to the bearish movement.

12.01.2026 - RMD Stock was down 5.1%

• The stock's decline could be linked to CEO Michael Farrell selling a significant number of shares, leading to investor concerns regarding the company's future.
• The reduction in ResMed's stake by Baader Bank Aktiengesellschaft may have also fueled negative sentiment, despite the company surpassing quarterly expectations.
• Market reaction to the ongoing clinical trial of ResMed's new software tool for sleep apnea patients might be influencing investor decisions, awaiting substantial results.
• Insider selling, institutional adjustments, and trial progress are potential factors contributing to today's bearish movement in ResMed's stock.

07.03.2025 - RMD Stock was up 5.7%

• Resmed's stock saw a rise following the successful launch of NightOwl, a home sleep apnea test, in the US.
• The FDA-cleared diagnostic tool is expected to boost the company's market presence and revenue prospects in the sleep apnea sector.
• Investor reactions indicate faith in Resmed's cutting-edge products and its capacity to meet the increasing need for in-home healthcare remedies.